Results 181 to 190 of about 3,761 (208)

Respiratory failure attributable to moxidectin intoxication in a dog

Journal of the American Veterinary Medical Association, 1999
A 5-month-old 22-kg (48.4-lb) sexually intact male Collie was examined after ingesting a moxidectin-containing deworming medication. The dog was comatose and had respiratory arrest after progressively worsening lethargy, ataxia, and seizures. Exposure was confirmed by isolation of moxidectin from a biopsy specimen of adipose tissue, using liquid ...
M W, Beal, R H, Poppenga, W J, Birdsall, D, Hughes   +3 more
openaire   +2 more sources

[Moxidectin poisoning in a foal?].

Tijdschrift voor diergeneeskunde, 1999
A 2 day old foal was presented with central nervous depression (coma) after moxidectin overdose. Moxidectin belongs to the milbemycin anthelmintics which elicit their working mechanism through a GABA (gamma-aminobutyric acid)-stimulatory mode of action. The foal developed profound hypothermia, bradycardia and hypoventilation.
L S, Goehring, M M, Sloet van Oldruitenborgh-Oosterbaan   +1 more
openaire   +1 more source

Extraction and analysis of moxidectin in wombat plasma and faeces

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Sarcoptic mange in wombats results from a skin infestation by Sarcoptes mites and if untreated, results in a slow and painful death. Moxidectin is a pesticide used to treat internal and external parasites in cattle, but has shown to effectively treat other animals, including wombats. Two methods were developed to analyse wombat plasma, and methods were
Gregory S Doran, Hayley J Stannard
exaly   +3 more sources

Loperamide‐induced enhancement of moxidectin availability in cattle

Journal of Veterinary Pharmacology and Therapeutics, 2002
Moxidectin (MXD) is a milbemycin endectocide compound active at extremely low dosages against a wide variety of nematode and arthropod parasites. Different pharmacological approaches are currently being tested to delay the bile‐faecal elimination and to obtain increased systemic availability for endectocide molecules in ruminants.
A, Lifschitz, G, Virkel, J, Sallovitz, F, Imperiale, A, Pis, C, Lanusse   +5 more
openaire   +2 more sources

The Antiparasitic Moxidectin: Safety, Tolerability, and Pharmacokinetics in Humans

The Journal of Clinical Pharmacology, 2003
A study in healthy male volunteers was completed to evaluate the safety, tolerability, and pharmacokinetics of a single oral dose of the antiparasitic moxidectin (MOX). This drug is registered worldwide as a veterinary antiparasitic agent for use in companion and farm animals. This is the first study of MOX in humans. All subjects were between the ages
Monette M, Cotreau, Sarah, Warren, John L, Ryan, Lawrence, Fleckenstein, Sreenivasa R, Vanapalli, Kenneth R, Brown, David, Rock, Chieh-Yu, Chen, Ullrich S, Schwertschlag   +8 more
openaire   +2 more sources

Evaluation of moxidectin for the treatment of internal parasites of cattle

New Zealand Veterinary Journal, 1992
Two groups of eight yearling Hereford cattle were used to assess the efficacy of injectable moxidectin in removing internal parasites. At 0.2 mg/kg liveweight, moxidectin was effective in ridding all eight treated animals of internal parasites in the abomasum, small and large intestines. The difference in worm counts between treated and control animals
D, Samson, W A, Charleston, W E, Pomroy, A M, Alexander   +3 more
openaire   +2 more sources

Moxidectin

2016
  +4 more sources

Moxidectin

2021
openaire   +1 more source

Moxidectin for deworming: from trials to implementation

The Lancet Infectious Diseases, 2018
Mathieu, Maheu-Giroux, Serene A, Joseph
openaire   +2 more sources

Use of moxidectin in goats in New Zealand

Veterinary Record, 1995
R M, Cobb, A W, Murphy
openaire   +2 more sources